If you take Xarelto and you are hoping a cheaper generic has finally arrived, the honest answer depends entirely on your dose — and for most people the generic does not yet apply. A generic version of rivaroxaban does exist as of 2025, but only as a 2.5 mg tablet, and only for a specific use. SunnyPharma built this guide from FDA, CMS, and manufacturer sources to explain which dose has a generic, why the others don’t, and the routes that actually lower your cost in the meantime.
The short version: if you take Xarelto for atrial fibrillation, DVT, or a pulmonary embolism, your dose is almost certainly 10, 15, or 20 mg — and there is no generic for those yet. The path to a lower price runs through the Medicare-negotiated price, manufacturer assistance, or a savings card, not the pharmacy generic shelf.
- Only the 2.5 mg dose has a generic — approved March 2025 (Lupin, Taro)
- The 2.5 mg is for CAD/PAD only, not the AFib/DVT/PE doses
- 10, 15, and 20 mg remain brand-only — patent-protected on once-daily dosing beyond 2025
- No announced date for a generic of the higher doses
- What lowers cost now: the Medicare-negotiated $197 price, patient assistance, or the commercial savings card
- Never switch your dose to chase a generic — and never stop Xarelto over cost (boxed warning: clot/stroke risk)
Which Xarelto Dose Has a Generic?
The FDA approved generic rivaroxaban in March 2025 — but only the 2.5 mg tablet. It is made by Lupin and by Taro (a Sun Pharma subsidiary), and it is approved for a narrower set of conditions than the doses most Xarelto patients take.
| Dose | Used for | Generic available? |
|---|---|---|
| 2.5 mg | Coronary artery disease (CAD) and peripheral artery disease (PAD), usually with aspirin | ✅ Yes — approved March 2025 |
| 10 mg | Preventing blood clots after hip or knee surgery; some long-term VTE prevention | ❌ No — brand-only |
| 15 mg | Atrial fibrillation; treating DVT and PE (with food) | ❌ No — brand-only |
| 20 mg | Atrial fibrillation; treating DVT and PE (with food) | ❌ No — brand-only |
So if you were prescribed Xarelto for an irregular heartbeat (AFib) or for a clot in your leg or lung, you are on a 15 or 20 mg dose, and there is no generic for it. The 2.5 mg generic that made headlines does not apply to you.
A note from the reviewer
Please don’t change your dose to match a cheaper one you’ve read about. The amount you were given is the amount that keeps you safe. If the price is the problem, let’s fix the price.
— Dr. Elizabeth Swiggum, MD, FRCPC, FCCS, cardiologist and heart failure specialist
Why Only the 2.5 mg Dose Went Generic
It comes down to patents, not to any difference in the medicine itself. Xarelto is developed and sold by Johnson & Johnson (through its Janssen division) together with Bayer. Protection on the 2.5 mg tablet lapsed enough for the FDA to approve generic competition in early 2025. But per Bayer, the 10, 15, and 20 mg tablets are protected by a patent on once-daily dosing that runs beyond 2025 — so generic manufacturers are legally blocked from selling those strengths even though the FDA pathway exists.
That is why Janssen still supplies essentially all of the higher-dose Xarelto in the country. There is no announced date for a generic of the 10, 15, or 20 mg doses; it depends on patent litigation and FDA review, neither of which moves on a public schedule.
What Xarelto Costs — and How to Lower It Without a Generic
Since most patients cannot use the generic, the real question is how to bring down the cost of brand-name Xarelto — and 2026 brought a significant change for Medicare beneficiaries.
Cost & access navigator
Answer one question and we’ll point you to the specific route for your Xarelto costs. Nothing is stored, no signup, no medication sold.
1 How is your prescription currently covered?
2 Is your household income at or below about 4× the federal poverty level?
Roughly $60,000 for one person or $124,000 for a family of four (2026). This only decides which program to check first — you enter no numbers.
Your route
Never stop taking your blood thinner to save money. Both Eliquis and Xarelto carry a boxed warning: stopping early raises the risk of clots and stroke. Use one of the routes above, or ask your prescriber about a lower-cost alternative — don’t go without.
Educational routing only — not medical advice, not a diagnosis, and not a pharmacy. SunnyPharma does not sell or ship medication. Figures reflect 2026 program terms and can change; confirm current details on the linked pages and the manufacturer sites.
The routes that actually lower your cost
- Medicare beneficiaries — the negotiated price: Xarelto was among the first drugs with a Medicare-negotiated price under the Inflation Reduction Act. $197 for a 30-day supply took effect January 1, 2026. That is what the government pays; your copay is set by your Part D plan, but your total Part D out-of-pocket is capped at $2,100 for the year.
- Uninsured — manufacturer patient assistance: The Johnson & Johnson Patient Assistance Foundation, through Janssen CarePath, provides Xarelto at no cost to qualifying patients who are uninsured or underinsured and meet income limits.
- Commercially insured — the savings card: The Xarelto withMe Savings Card can reduce your copay to as little as $0–$10 per fill. Private insurance only — it cannot be used with Medicare, Medicaid, or other government coverage.
- Discuss alternatives with your clinician: If cost is a real barrier, a clinician can discuss whether a different anticoagulant with a full generic line is appropriate for you. That is a clinical decision, not a do-it-yourself swap.
Never stop taking Xarelto because of cost. Xarelto carries an FDA boxed warning that stopping it early raises the risk of blood clots and stroke. If you cannot afford it, talk to your clinician or pharmacist before skipping or stopping doses — one of the pathways above almost always fits, and a clinician can discuss a lower-cost anticoagulant rather than leaving you untreated.
Is the Generic as Good as Brand-Name Xarelto?
For the dose it covers, yes — there is no quality compromise. An FDA-approved generic must contain the same active ingredient, be absorbed the same way (bioequivalence), and meet the same manufacturing-quality standards as the brand. Generic rivaroxaban 2.5 mg is a genuine equal substitute for Xarelto 2.5 mg for its approved CAD and PAD uses.
The only limitation is which strengths are available, not how well they work. Patients who legitimately take the 2.5 mg dose can switch with confidence; everyone else is waiting on availability, not quality.
Frequently Asked Questions
Is there a generic for Xarelto?
Partly. The FDA approved the first generic rivaroxaban in March 2025, but only the 2.5 mg tablet, and only for coronary artery disease (CAD) and peripheral artery disease (PAD). The 10 mg, 15 mg, and 20 mg doses used for atrial fibrillation, DVT, and PE remain brand-only, because Johnson & Johnson and Bayer hold patent protection on the once-daily dosing of those strengths beyond 2025. So most people taking Xarelto cannot yet switch to a generic, and need other ways to lower cost.
Can I switch to generic rivaroxaban to save money?
Only if you take the 2.5 mg dose for coronary or peripheral artery disease. If you take Xarelto 10, 15, or 20 mg for atrial fibrillation, DVT, or PE, there is no generic version of your dose, and substituting the 2.5 mg generic is not appropriate because it is a different strength for a different purpose. Never change your dose to chase a generic price. If cost is the issue, the better routes are the Medicare-negotiated price, manufacturer patient assistance, or a commercial savings card.
When will a generic for Xarelto 20 mg be available?
No date has been announced. The 10, 15, and 20 mg strengths are protected by patents on once-daily dosing that Bayer and Johnson & Johnson hold beyond 2025, and the timeline depends on patent litigation and FDA review. Until that resolves, the reliable ways to lower cost on the higher Xarelto doses are the Medicare-negotiated price, manufacturer patient assistance for the uninsured, and a commercial savings card for the privately insured.
What happens if I stop taking Xarelto because of cost?
Stopping Xarelto because of cost is dangerous. Xarelto carries an FDA boxed warning that stopping it early raises the risk of blood clots and stroke. If cost is the barrier, talk to your clinician or pharmacist before skipping or stopping doses, and use the cost pathways first: the Medicare-negotiated price, the Part D out-of-pocket cap, manufacturer patient assistance, or a commercial savings card. A clinician can also discuss whether a different, lower-cost anticoagulant is appropriate rather than going without treatment.
Related Anticoagulant Guides
How we reviewed this article:
SunnyPharma follows strict sourcing guidelines and relies on government agencies (FDA, CMS/Medicare) and official manufacturer program documentation. Dr. Swiggum’s review covers the clinical content; cost, coverage, and generic-status details are drawn from FDA, CMS, and manufacturer sources. We use only credible, verifiable sources to ensure accuracy.
Reviewer disclosure: Dr. Swiggum has disclosed financial relationships with Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer, and GSK, including work related to dabigatran, an anticoagulant that competes with the medication discussed here. Her review is limited to clinical accuracy and does not involve SunnyPharma’s editorial or cost-pathway recommendations.
Read our editorial policy →Sources & References
- FDA — Xarelto (rivaroxaban) Prescribing Information (boxed warning, indications by dose): accessdata.fda.gov
- FDA — first generic rivaroxaban 2.5 mg approval (CAD/PAD), March 2025: fda.gov
- Medicare — Drug Price Negotiation Program (Xarelto negotiated price effective 2026): cms.gov
- CMS — Draft CY 2026 Part D Redesign Program Instructions Fact Sheet (annual out-of-pocket threshold $2,100): cms.gov
- Medicare.gov — Costs for Medicare drug coverage (Part D) and the out-of-pocket cap: medicare.gov
- Johnson & Johnson Patient Assistance Foundation (Xarelto, uninsured patients): jjpaf.org
- Xarelto — official patient site and withMe Savings Card (Janssen): xarelto-us.com
- HHS Office of Inspector General — copay coupons and the federal anti-kickback statute: oig.hhs.gov
- NIH MedlinePlus — Rivaroxaban: medlineplus.gov
- FDA — Generic drugs: questions & answers (bioequivalence standards): fda.gov